Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 17:19:04 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Antibiotic resistance nearly killed me, so I'm raising awareness of it

Wikipedia

WSS

Chamber of Commerce, DOJ clash in court over drug prices

Akili changes sales model for its ADHD video game treatment

How the messy conversation about Dolly changed bioethics

Startling documents reveal new facets of Sacklers' opioid empire

Biohaven protein

Why the drug industry's warnings on the IRA's impact fall short

knowledge

Wikipedia

focus

Peter Hotez and the public health issue of online harassment

Dark money group runs ads on China biotech bill

Walensky prepares to leave CDC — and Congress — behind

Grad students accuse University of California of wage theft

Bright Health sells Medicare Advantage business to Molina

Insmed lung disease drug hits target in key Phase 3 trial

State Dept. review finds Biden bears some blame for Afghanistan failures

Insmed lung disease drug hits target in key Phase 3 trial

Drug repurposing or repositioning? The language matters

Transgender sports debate: Physicians say bans are health issue

focus

David Sabatini, ex

Biohaven protein

Do more moles mean more problems? Not so, says new study

What happened to the House vote on health price transparency?

The unintended consequences of overturning Roe v. Wade

Insmed lung disease drug hits target in key Phase 3 trial

leisure time

hotspot

Wikipedia

hotspot